Xue-Mei Jiang1, Xiang-Nan Yu1,2, Ren-Zheng Huang2, Hai-Rong Zhu2, Xiao-Peng Chen1, Ju Xiong3, Zheng-Yi Chen1, Xiao-Xi Huang1, Xi-Zhong Shen2,4,5, Ji-Min Zhu6. 1. Department of Gastroenterology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, 570028, China. 2. Department of Gastroenterology, Zhongshan Hospital of Fudan University, 180 Fenglin Rd., Shanghai, 200032, China. 3. Department of General Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, 830001, China. 4. Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai, China. 5. Key Laboratory of Medical Molecular Virology, Shanghai Medical College of Fudan University, Shanghai, China. 6. Department of Gastroenterology, Zhongshan Hospital of Fudan University, 180 Fenglin Rd., Shanghai, 200032, China. zhu.jimin@zs-hospital.sh.cn.
Abstract
PURPOSE: Aberrant expression of eukaryotic initiation factor 4E (eIF4E) has been observed in human malignancies. However, its role in hepatocellular carcinoma (HCC) remains to be established. The purpose of this study was to detect eIF4E expression and to evaluate its clinical relevance. METHODS: The eIF4E expression was studied in ninety HCC and randomly selected thirty-one non-tumor tissues from the same patient cohort, as well as in normal hepatic and HCC cell lines. The relation between its expression and clinicopathological parameters was also analyzed. RESULTS: eIF4E expression was higher in HCC samples and cell lines compared with that in non-tumor tissues (P < 0.001) and hepatocyte LO2, respectively. eIF4E overexpression was significantly associated with tumor number (P = 0.005) and incomplete encapsulation (P = 0.001). The 5-year overall survival rate and disease-free survival rate for patients with high eIF4E expression were 32.5 and 31.2 %, respectively; and for low eIF4E expression, it was 67.9 and 64.4 %, respectively (P < 0.001). Furthermore, subgroup analysis showed that high eIF4E level predicted poorer overall survival only for incomplete encapsulation (P = 0.001) and cirrhosis (P < 0.001), but not for complete encapsulation (P = 0.804) and non-cirrhosis (P = 0.359). Multivariate analysis revealed that eIF4E overexpression was an independent indicator for both overall survival (hazard ratio, 2.015; P = 0.043) and disease-free survival (hazard ratio, 2.666; P = 0.006). CONCLUSIONS: eIF4E protein might result in the malignant progression of HCC, and its overexpression may be a powerful prognostic biomarker and therapeutic target for HCC patients.
PURPOSE: Aberrant expression of eukaryotic initiation factor 4E (eIF4E) has been observed in humanmalignancies. However, its role in hepatocellular carcinoma (HCC) remains to be established. The purpose of this study was to detect eIF4E expression and to evaluate its clinical relevance. METHODS: The eIF4E expression was studied in ninety HCC and randomly selected thirty-one non-tumor tissues from the same patient cohort, as well as in normal hepatic and HCC cell lines. The relation between its expression and clinicopathological parameters was also analyzed. RESULTS:eIF4E expression was higher in HCC samples and cell lines compared with that in non-tumor tissues (P < 0.001) and hepatocyte LO2, respectively. eIF4E overexpression was significantly associated with tumor number (P = 0.005) and incomplete encapsulation (P = 0.001). The 5-year overall survival rate and disease-free survival rate for patients with high eIF4E expression were 32.5 and 31.2 %, respectively; and for low eIF4E expression, it was 67.9 and 64.4 %, respectively (P < 0.001). Furthermore, subgroup analysis showed that high eIF4E level predicted poorer overall survival only for incomplete encapsulation (P = 0.001) and cirrhosis (P < 0.001), but not for complete encapsulation (P = 0.804) and non-cirrhosis (P = 0.359). Multivariate analysis revealed that eIF4E overexpression was an independent indicator for both overall survival (hazard ratio, 2.015; P = 0.043) and disease-free survival (hazard ratio, 2.666; P = 0.006). CONCLUSIONS:eIF4E protein might result in the malignant progression of HCC, and its overexpression may be a powerful prognostic biomarker and therapeutic target for HCC patients.
Authors: Tanasa S Osborne; Ling Ren; John H Healey; Lauren Q Shapiro; Alexander J Chou; Richard G Gorlick; Stephen M Hewitt; Chand Khanna Journal: J Pediatr Hematol Oncol Date: 2011-10 Impact factor: 1.289
Authors: Jeremy R Graff; Bruce W Konicek; Rebecca L Lynch; Chad A Dumstorf; Michele S Dowless; Ann M McNulty; Stephen H Parsons; Leslie H Brail; Bruce M Colligan; Jonathan W Koop; Bernadette M Hurst; James A Deddens; Blake L Neubauer; Louis F Stancato; Harry W Carter; Larry E Douglass; Julia H Carter Journal: Cancer Res Date: 2009-04-21 Impact factor: 12.701
Authors: Jeremy R Graff; Bruce W Konicek; Thomas M Vincent; Rebecca L Lynch; David Monteith; Spring N Weir; Phil Schwier; Andrew Capen; Robin L Goode; Michele S Dowless; Yuefeng Chen; Hong Zhang; Sean Sissons; Karen Cox; Ann M McNulty; Stephen H Parsons; Tao Wang; Lillian Sams; Sandaruwan Geeganage; Larry E Douglass; Blake Lee Neubauer; Nicholas M Dean; Kerry Blanchard; Jianyong Shou; Louis F Stancato; Julia H Carter; Eric G Marcusson Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808
Authors: Santiago Ramon Y Cajal; Josep Castellvi; Stefan Hümmer; Vicente Peg; Jerry Pelletier; Nahum Sonenberg Journal: Oncogene Date: 2018-02-21 Impact factor: 9.867